GlassScriptPhysician profile
Michael Neville
NPI 1174800155
$849.59
in general payments reported to CMS, 2019-2025
14 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $511 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $255.94 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $100.14 | 2024-2025 | Voquezna |
| Amgen INC. | $96.42 | 2024-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $73.01 | 2024-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $60.31 | 2024 | Spravato |
| Abbvie INC. | $53.79 | 2024-2025 | |
| Viiv Healthcare Company | $45.49 | 2024 | Apretude |
| Pfizer INC. | $39.81 | 2024-2025 | |
| Novo Nordisk INC | $30.25 | 2024 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $28.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $15.87 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $13.88 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Neville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.